Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Value Health Reg Issues ; 41: 63-71, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38241886

RESUMO

OBJECTIVES: The objective of this study was to identify the association between healthcare fragmentation and survival for patients with colorectal cancer in Colombia. METHODS: A retrospective cohort study was performed using administrative databases, with an electronic algorithm to identify patients with colorectal cancer based on codes. The patients were enrolled between January 1, 2013, and December 31, 2016. The exposure variable was fragmentation, which was measured based on the number of different healthcare institutions that treated a patient during the first year after diagnosis. Matching was performed using propensity scores to control for confounding, and the hazard ratio for exposure to higher fragmentation was calculated for the matched sample. RESULTS: A total of 5036 patients with colorectal cancer were identified, 2525 (49.88%) of whom were women. The mean number of network healthcare institutions for the total sample was 5.71 (SD 1.98). The patients in the quartile with higher fragmentation had the highest mortality rate, 35.67 (95% CI 33.63-38.06) per 100 patients. The comparison of higher and lower quartiles of fragmentation resulted in an incidence rate ratio of 1.23 (95% CI 1.04-1.45; P = .02). Of the 5036 patients, 422 (8.38%) were classified as the exposed cohort (higher fragmentation). The total matched sample consisted of 844 subjects, and an HR of 1.26 (95%CI; 1.05-1.51) was estimated. CONCLUSIONS: Exposure to more highly fragmented healthcare networks decreases overall 4-year survival for patients with colorectal cancer in Colombia.


Assuntos
Neoplasias Colorretais , Humanos , Neoplasias Colorretais/mortalidade , Colômbia/epidemiologia , Feminino , Masculino , Estudos Retrospectivos , Pessoa de Meia-Idade , Idoso , Adulto , Pontuação de Propensão
2.
Colomb Med (Cali) ; 53(1): e2074873, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36452117

RESUMO

Objective: To analyze the cervix cancer mortality in Colombia, based on age, period and cohort effects. Methods: The mortality and population data were taken from the official databases of the National Administrative Department of Statistics, DANE. Five models were adjusted, the significance of the effects was obtained by comparing them through the likelihood ratio test. Results: The age-adjusted mortality rate, in deaths was 15.09/100,000 woman, at 1985-1989 period, and 10.21 at 2010-2014 period. The annual percentage average change was -1.45% (95% CI: -1.57% to -1.34%). Age, period and cohort effects were found. Conclusions: Demographic factors could explain the behavior of cervical cancer mortality in Colombia, as well as the establishment of public health measures in the last two decades.


Objetivo: Analizar las tendencias de la mortalidad por cáncer de cuello uterino en Colombia, teniendo en cuenta los efectos de edad, periodo y cohorte. Métodos: Los datos de mortalidad y de población se tomaron de las bases oficiales del Departamento Administrativo Nacional de Estadísticas, DANE. Se ajustaron cinco modelos, la significancia de los efectos se obtuvo comparándolos a través de la prueba de razón de verosimilitud. Resultados: La tasa de mortalidad ajustada por edad, en muertes fue de 15.09/100,000 mujeres, para el periodo 1985-1989 y 10.21 para el periodo 2010-2014. El cambio promedio porcentual anual fue de -1.45% (IC 95%: -1.57% a -1.34%). Se encontraron efectos de edad, periodo y cohorte. Conclusiones: Los factores demográficos podrían explicar el comportamiento de la mortalidad por cáncer de cuello uterino en Colombia, al igual que la instauración de medidas de salud pública en las dos últimas décadas.


Assuntos
Neoplasias do Colo do Útero , Feminino , Humanos , Efeito de Coortes , Neoplasias do Colo do Útero/epidemiologia , Colômbia/epidemiologia , Saúde Pública
3.
Colomb. med ; 53(1): e2074873, Jan.-Mar. 2022. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1404381

RESUMO

Abstract Objective: To analyze the cervix cancer mortality in Colombia, based on age, period and cohort effects. Methods: The mortality and population data were taken from the official databases of the National Administrative Department of Statistics, DANE. Five models were adjusted, the significance of the effects was obtained by comparing them through the likelihood ratio test. Results: The age-adjusted mortality rate, in deaths was 15.09/100,000 woman, at 1985-1989 period, and 10.21 at 2010-2014 period. The annual percentage average change was -1.45% (95% CI: -1.57% to -1.34%). Age, period and cohort effects were found. Conclusions: Demographic factors could explain the behavior of cervical cancer mortality in Colombia, as well as the establishment of public health measures in the last two decades.


Resumen Objetivo: Analizar las tendencias de la mortalidad por cáncer de cuello uterino en Colombia, teniendo en cuenta los efectos de edad, periodo y cohorte. Métodos: Los datos de mortalidad y de población se tomaron de las bases oficiales del Departamento Administrativo Nacional de Estadísticas, DANE. Se ajustaron cinco modelos, la significancia de los efectos se obtuvo comparándolos a través de la prueba de razón de verosimilitud. Resultados: La tasa de mortalidad ajustada por edad, en muertes fue de 15.09/100,000 mujeres, para el periodo 1985-1989 y 10.21 para el periodo 2010-2014. El cambio promedio porcentual anual fue de -1.45% (IC 95%: -1.57% a -1.34%). Se encontraron efectos de edad, periodo y cohorte. Conclusiones: Los factores demográficos podrían explicar el comportamiento de la mortalidad por cáncer de cuello uterino en Colombia, al igual que la instauración de medidas de salud pública en las dos últimas décadas.

4.
Rev. colomb. anestesiol ; 50(1): e203, Jan.-Mar. 2022. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1360947

RESUMO

Abstract Introduction: Access to essential medicines, including opioids, is a component of the right to health. Objective: To identify barriers to opioid availability and accessibility for pain and palliative care. Methods: Online survey with Colombian prescribers. Availability barriers were analyzed for each facility (distribution and/or dispensing). Accessibility barriers were analyzed by type. Descriptive analyses were conducted using relative frequencies. Significance within categories and regions was measured using Fisher's exact test. Results: Out of 1,208 prescribers invited, 806 (66.7%) completed the survey. Availability: 76.43% reported barriers. The most cited barrier was "Pharmacies authorized by health insurance companies", where opioids are frequently unavailable. Accessibility: 74.6% reported barriers. Most frequently cited was "Difficulty securing payment authorization for medication from health insurance companies". Significant differences were observed in terms of regions and "Cost" (p=0.02). Lack of coordination among procuring and distributing agencies affects availability. Limited awareness and bureaucratic procedures affect accessibility. Conclusions: There are barriers to opioid availability and access in Colombia, related to the existing structure for guaranteeing equitable supply. From the perspective of healthcare providers, problems related to pharmacy availability, prescription and cost of medicines hinder pain treatment.


Resumen Introducción: El acceso a medicamentos esenciales, incluidos los opioides, es un componente del derecho a la salud. Objetivo: Identificar las barreras de disponibilidad y acceso a los opioides para dolor y cuidados paliativos. Métodos: Encuesta virtual a prescriptores colombianos. Las barreras de disponibilidad se analizaron para cada centro (distribución y/o dispensación) y las barreras de acceso se analizaron por tipo. Los análisis descriptivos se realizaron utilizando frecuencias relativas. La significancia dentro de categorías y regiones se midió utilizando la prueba exacta de Fischer. Resultados: De los 1208 prescriptores invitados, 806 (66.7%) respondieron la encuesta. Disponibilidad: el 76,43% reportó barreras. La barrera más citada fue la relacionada con las "farmacias autorizadas por las aseguradoras de salud", donde los opioides con frecuencia no están disponibles. Acceso: el 74,6% reportó barreras. Se citó con mayor frecuencia la "Dificultad para obtener la autorización de pago de medicamentos por parte de las aseguradoras". Se observaron diferencias significativas entre regiones y "costos" (p=0,02). La falta de coordinación entre las entidades de adquisición y distribución afecta la disponibilidad. La limitada conciencia y los procedimientos burocráticos afectan la accesibilidad. Conclusiones: Existen barreras de disponibilidad y acceso a los opioides en Colombia, las cuales están relacionadas con la estructura disponible para garantizar un suministro equitativo. Desde el punto de vista de los prescriptores, los problemas relacionados con la disponibilidad de las farmacias, la prescripción y el costo de los medicamentos, obstaculizan el tratamiento adecuado del dolor.


Assuntos
Pâncreas Divisum
5.
Salud UNINORTE ; 36(1): 46-61, ene.-abr. 2020. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1252121

RESUMO

RESUMEN Objetivo: La automedicación en niños tiene una prevalência mundial del 50 %. La enfermedad diarreica aguda y la infección del tracto respiratorio son enfermedades prevalentes de la infancia, y se ven afectadas por esta práctica. El objetivo fue establecer la prevalencia de automedicación en niños que consultan a un servicio de pediatría y explorar posibles factores asociados. Materiales y métodos: Se realizó un estudio de corte transversal. Se incluyeron niños que consultaron por infección respiratoria aguda y/o enfermedad diarreica aguda. Se desarrolló un instrumento (encuesta) para la recolección de la información. Con el objetivo de explorar los posibles factores asociados con la automedicación se realizaron análisis bivariados y se construyó un modelo de regresión logística. Se estimó como medida de efecto el OR con su intervalo de confianza. Se estableció el valor de significancia estadística con un valor de p< 0,05. Resultados: Se incluyeron 300 menores. La prevalencia de automedicación fue del 46 %. Los medicamentos más usados fueron el acetaminofén (78 %) y el ibuprofeno (15 %). Se encontró posible asociación de la automedicación con el antecedente de previo de automedicación y la edad del niño. Conclusiones: La prevalencia de automedicación es alta y similar a la encontrada en la literatura. Los posibles factores asociados a la automedicación en niños son la experiencia previa de automedicación y la edad del niño. Desde la atención primaria se deben realizar campañas educativas a la población de los riesgos de la automedicación.


ABSTRACT Objective: Self-medication in children has a worldwide prevalence of 50%. Acute diarrheal disease and respiratory tract infection are prevalent childhood diseases and are affected by this practice. The objective was established the prevalence of self-medication in children who consult a pediatric service and explore possible associated factors. Materials and methods: A cross-sectional study was conducted, children who consulted for acute respiratory disease or acute diarrheal disease were included. An instrument for information collection was developed and applied. In order to explore the possible risk factors associated with self-medication, bivariate analyzes were performed and a logistic regression model was constructed. The OR with its confidence interval was estimated as an effect measure. The statistical significance value was established with a value of p <0.05. Results: 300 children were included. The prevalence of self-medication was 46 %. The most used medications were acetaminophen (78 %) and ibuprofen (15 %). Association of self-medication was found with the history of prior self-medication and the child's age. Conclusions: The prevalence of self-medication is high and like that found in the literature. Possible associated factors are previous self-medication experience and the child's age. From primary care it is appropriate to carry out educational campaigns to the population of the risks of self-medication.

6.
Rev. colomb. obstet. ginecol ; 66(4): 287-296, oct.-dic. 2015. tab
Artigo em Espanhol | LILACS | ID: lil-775943

RESUMO

Describir variantes de secuencia en los genes BRCA1 y BRCA2 en una muestra de pacientes colombianas con historia personal o familiar de cáncer de mama sugestiva de riesgo genético.Materiales y métodos: serie de casos compuesta por 67 pacientes que fueron remitidas para estudio genético por sospecha de síndrome de cáncer de mama y ovario hereditario (HBOC). De los 67 casos, 42 (62,7 %) cumplieron con los criterios de indicación médica de la National Comprehensive Cancer Network (NCCN) del 2013, y en ellos se realizó secuenciación completa de los genes BRCA1 y BRCA2. Se determinó la frecuencia de mutación, variantes de secuencia y significancia clínica de las variantes halladas con base en Breast Cancer Information Core (BIC).Resultados: se identificaron mutaciones para el gen BRCA1 en seis pacientes (14,3 %), no se documentó mutación para el gen BRCA2, además se detectaron 43 variantes genéticas en 27 pacientes (64,2 % de 42 casos). De estas, 21 (48,8 %) fueron identificadas en el gen BRCA1 y 22 (51,2 %) en el gen BRCA2. Dentro de estas variantes, se identificaron 5 mutaciones patogénicas solo en el gen BRCA1, de las cuales solo una había sido reportada previamente en Colombia.Conclusiones: este estudio identifica variantes genéticas patogénicas en el gen BRCA1 no descritas en estudios previos en la población colombiana y otras conocidas en diferentes poblaciones; permitiendo de esta forma ampliar el conocimiento sobre las variantes en población colombiana de los genes BRCA1 y BRCA2. Sin embargo, se requieren más estudios con suficiente poder y calidad metodológica para poder estimar la frecuencia de mutaciones y de variantes de secuencia para estos genes en mujeres colombianas con sospecha de síndrome de cáncer de mama u ovario hereditario...


To describe sequence variants in the BRCA1 and BRCA2 genes in a sample of Colombian patients with a personal or family history of breast cancer suggestive of genetic risk.Materials and methods: Case series consisting of 67 patients referred for genetic testing because of suspected hereditary breast and ovarian cancer syndrome (HBOC). Of the 67 cases, 42 (62.7%) met the medical indication criteria of the 2013 National Comprehensive Cancer Network (NCCN) and they were subjected to the entire sequencing of the BRCA1 and BRCA2 genes. A determination was made of the frequency of sequence mutation, variants, and of the clinical significance of the variants found based on the Breast Cancer Information Core (BIC).Results: Mutations were identified for the BRCA 1 gene in six patients (14.3%), no mutation was documented for the BRCA 2 gene, and 43 genetic variants were found in 27 patients (64.2% of 42 cases). Of these, 21 (48.8%) were identified in the BRCA1 gene and 22 (51.2%) in the BRCA 2 gene. Among these variants, 5 pathogenic mutations were found only in the BRCA1 gene and, of those, only 1 had been reported previously in Colombia.Conclusions: This study identifies pathogenic genetic variants in the BRCA1 gene not described previously in the Colombian population, as well as others known in different populations. Therefore, it helps expand knowledge regarding the variants of the BRCA1 and BRCA2 genes in the Colombian population. However, additional studies are required with sufficient power and methodological quality to estimate the frequency of sequence mutations and variants for the BRCA1 and BRCA2 genes in Colombian women suspected of having the hereditary breast or ovarian cancer syndrome...


Assuntos
Adulto , Feminino , Neoplasias da Mama , Genes BRCA1
7.
Vaccine ; 31(2): 402-9, 2013 Jan 02.
Artigo em Inglês | MEDLINE | ID: mdl-23174195

RESUMO

OBJECTIVE: Varicella vaccination has not been introduced worldwide, especially in developing countries. The present study assesses the potential epidemiological and economic impact of one-dose and two-dose varicella vaccination schemes in Colombia, a south American upper middle-income country. METHODS: A decision-tree based model was developed. Varicella cases were estimated based on previous reports of seropositivity within the country. Cost per life-year gained (LYG) was the main outcome measure. Costs from the health care system perspective were expressed in 2008 American dollars. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: In Colombia, there would be 700,197 varicella cases in an average year plus 60 yearly deaths without vaccination. It was estimated that health care costs for all cases during 30 years period could be around US $88,734,735 (with discount). Cost per LYG of one-dose vaccination was US $2519 and using a two-dose scheme was US $5728. CONCLUSION: Vaccinating against varicella in Colombia, an upper middle-income South American country is cost-effective under the assumptions used in this study. Decision-makers should consider introducing universal varicella vaccination in Colombia, given the effectiveness, safety and cost-effectiveness of this intervention.


Assuntos
Vacina contra Varicela/administração & dosagem , Vacina contra Varicela/economia , Varicela/economia , Varicela/prevenção & controle , Varicela/epidemiologia , Varicela/imunologia , Vacina contra Varicela/imunologia , Colômbia/epidemiologia , Análise Custo-Benefício , Custos e Análise de Custo/economia , Árvores de Decisões , Países em Desenvolvimento/economia , Humanos , Modelos Estatísticos , Vacinação/economia
8.
Value Health Reg Issues ; 1(2): 190-200, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29702900

RESUMO

OBJECTIVE: To evaluate the cost-effectiveness of different screening strategies for colorectal cancer in Colombia. METHODS: We designed a Markov model to compare the clinical and economic impact in terms of reducing the incidence and mortality from colorectal cancer (CRC). Six screening strategies for adults were compared: fecal occult blood (FOBT) immunochemical and guaiac type, conventional colonoscopy, flexible sigmoidoscopy, and FOBT guaiac and immunochemical type more sigmoidoscopy. We used the third-party payer perspective, including only direct costs, the time horizon was the life expectancy of the Colombian population. We estimated cost-effectiveness ratios (CERs) and incremental cost-effectiveness (ICER). Were performed deterministic sensitivity analysis and probabilistic. We applied a discount rate of 3% in the costs and health outcomes. RESULTS: The screening strategy more cost-effective was the FOBT biennial guaiac type. The cost per life year gained was US$10,347.37, US$18,380.64, and US$45,158.05. For FOBT guaiac biennial, FOBT guaiac annual and FOBT inmunoquímica biennial respectively. The ICER is sensitive to the percentage of false positive test for FOBT guaiac type values greater than 10%, and the cost of the test. CONCLUSIONS: The screening strategy more cost-effective for Colombia is the FOBT biennial guaiac type, using as a threshold the gross domestic product (GDP) per capita in Colombia.

9.
Rev. salud pública ; 12(6): 974-981, dic. 2010. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-602845

RESUMO

Objetivo Analizar, desde la perspectiva del pagador, la costo efectividad de la adición de resonancia magnética a la radiografía convencional en pacientes con pie diabético y signos de infección, en Colombia. Métodos Mediante un modelo de Markov, se identificó la relación de costo-efectividad de la adición de resonancia magnética a la radiografía convencional en pacientes con pie diabético y signos de infección en Colombia. La perspectiva es la del pagador. Los costos se valoraron en pesos colombianos de 2008, la efectividad se mide en años de vida ajustados por discapacidad, AVAD y el umbral de costo efectividad fue el PIB per cápita colombiano de 2008, $ 10 761 691. Resultados Usar resonancia magnética además de radiografía convencional en estos pacientes tiene un indicador de costo efectividad incremental por AVAD de $ 1 532 778 y de $ 1 741 311 sin y con descuento respectivamente. Los resultados son robustos a pruebas de sensibilidad. Conclusiones La resonancia magnética unida a la radiografía convencional en la evaluación del pie diabético con signos de infección es costo-efectiva para Colombia.


Objective Performing a cost-effectiveness analysis of adding magnetic resonance to conventional radiography in patients suffering from diabetic foot and signs of infection from the payer's point of view. Material and methods The cost effectiveness (from the payer's point of view) of conventional radiography plus magnetic resonance was calculated for patients having diabetic foot and signs of infection by means of a Markov model. Costs were measured in 2008 Colombian pesos and effectiveness in terms of disability adjusted life years (DALY). The cost-effectiveness threshold was the Colombian 2008 per capita GDP, $ 10,761,691. Results Using magnetic resonance in addition to conventional radiography in this population had a $ 1,532,778 and $ 1,741,311 incremental cost-effectiveness ratio, without and with discount, respectively; the results were robust to sensitivity analysis. Conclusions Using magnetic resonance in addition to conventional radiography in patients suffering from diabetic foot and signs of infection was cost-effective for Colombia.


Assuntos
Humanos , Pessoa de Meia-Idade , /complicações , Pé Diabético/diagnóstico , Imageamento por Ressonância Magnética/economia , Radiografia/economia , Colômbia , Análise Custo-Benefício , Pé Diabético , Cadeias de Markov , Modelos Econômicos , Anos de Vida Ajustados por Qualidade de Vida
10.
Rev Salud Publica (Bogota) ; 12(6): 974-81, 2010 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-22030684

RESUMO

OBJECTIVE: Performing a cost-effectiveness analysis of adding magnetic resonance to conventional radiography in patients suffering from diabetic foot and signs of infection from the payer's point of view. MATERIAL AND METHODS: The cost effectiveness (from the payer's point of view) of conventional radiography plus magnetic resonance was calculated for patients having diabetic foot and signs of infection by means of a Markov model. Costs were measured in 2008 Colombian pesos and effectiveness in terms of disability adjusted life years (DALY). The cost-effectiveness threshold was the Colombian 2008 per capita GDP, $ 10,761,691. RESULTS: Using magnetic resonance in addition to conventional radiography in this population had a $ 1,532,778 and $ 1,741,311 incremental cost-effectiveness ratio, without and with discount, respectively; the results were robust to sensitivity analysis. CONCLUSIONS: Using magnetic resonance in addition to conventional radiography in patients suffering from diabetic foot and signs of infection was cost-effective for Colombia.


Assuntos
Diabetes Mellitus Tipo 2/complicações , Pé Diabético/diagnóstico , Imageamento por Ressonância Magnética/economia , Radiografia/economia , Colômbia , Análise Custo-Benefício , Pé Diabético/diagnóstico por imagem , Humanos , Cadeias de Markov , Pessoa de Meia-Idade , Modelos Econômicos , Anos de Vida Ajustados por Qualidade de Vida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA